HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Puma Biotechnology (NASDAQ:PBYI) and maintained an $8 price target.
February 13, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterated a Buy rating on Puma Biotechnology with an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst could positively influence investor sentiment towards PBYI, potentially leading to a short-term increase in its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100